Toshiba and GE Vernova Sign MoU to advance carbon reduction and efficiency for gas turbine fired power plants in Japan and other parts of Asia

by | PRNewswire Asia

Objective of the Memorandum of Understanding (MoU) is to reduce CO2 emissions combining GE Vernova’s Exhaust Gas Recirculation (EGR) system and Toshiba’s CO2 capture technologies in natural gas fired power plants in Japan and other parts of Asia. The MoU...

APR Corp. maintains its history of record-breaking financial performance also in Q3 2025, anticipating exceeding KRW 1 trillion revenue by the end of the year

by | PRNewswire Asia

Q3 2025; revenue KRW 385.9 bn while Operating Profit KRW 96.1 bn, according to Provisional performance based on consolidation. A new quarter financial record compared to the same period last year, 122% increased revenue, 253% increased operating profit…...

New Regional Certifications to Boost Healthcare Training Standards Across Southeast Asia

by | PRNewswire Asia

Two new specially designed certification programmes will train doctors, nurses and technical specialists across the region in simulation-based medical education. SINGAPORE, Nov. 6, 2025 /PRNewswire/ — The first healthcare simulation certification programmes...

2025 Taiwan Innotech Expo Attracts 50,000+ from 65 Countries; Exhibitions Showcase the Power of AI in Driving Cross-Sector Innovations and Accelerating Upgrades in Taiwan's Industries

by | PRNewswire Asia

TAIPEI, Nov. 6, 2025 /PRNewswire/ — The 2025 Taiwan Innotech Expo (TIE) successfully concluded on October 18, drawing over 50,000 visitors from 65 countries. The event featured 422 companies and academic institutions from 19 countries, exhibiting 1,100...

IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025

by | PRNewswire Asia

Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics Strengthening global CDMO strategy through strategic synergy with SK bioscience Sustainable growth expected, backed by European commercial manufacturing...

HanchorBio Presents Preclinical Data on HCB301 at SITC 2025

by | PRNewswire Asia

HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPα-CD47, PD-1/PD-L1, and TGFβ; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. TAIPEI, SHANGHAI, and SAN FRANCISCO,...